AbbVie: in Phase 3 TEMPLE, QULIPTA beat topiramate on tolerability in migraine prevention
In the Phase 3 TEMPLE trial, 12% of adults on atogepant (QULIPTA) stopped treatment because of side effects, versus 30% on topiramate, over a 24-week blinded period.
AbbVie (NYSE: ABBV) reported positive results of the Phase 3 TEMPLE trial of QULIPTA (atogepant) for migraine prevention, according to finance.yahoo.com. The study compared the drug head to head with topiramate in adults with migraine. The report was published on 12 November 2026. finance.yahoo.com
finance.yahoo.comfinance.yahoo.comOpen source ↗
The company's announcement covers two outcomes: tolerability and efficacy. Both favored QULIPTA over the comparator.
Tolerability and efficacy results
During the 24-week blinded period, 12% of patients taking atogepant stopped treatment because of side effects. On topiramate the figure was 30%. On this measure, the TEMPLE study found QULIPTA to have superior tolerability.
QULIPTA also showed better efficacy than topiramate on key migraine prevention endpoints. finance.yahoo.com
finance.yahoo.comfinance.yahoo.comOpen source ↗ The material does not give numerical values for these endpoints, so the size of the difference is not specified.
QULIPTA is an oral drug. The publication notes that many patients find it hard to stay on older drugs, and that the TEMPLE data give an oral option with better tolerability and stronger prevention endpoints.
Context for AbbVie
AbbVie is a large research-based biopharmaceutical group that develops and sells medicines across several therapy areas. Migraine is one of the chronic conditions it focuses on, and QULIPTA sits alongside Ubrelvy in this area.
The publication also points to AbbVie's 2026 guidance of about US$67.8b in net revenues, which already reflects QULIPTA and other drugs. finance.yahoo.com
finance.yahoo.comfinance.yahoo.comOpen source ↗ A single trial result does not replace sales data.
To see how the result translates into sales, the source suggests watching AbbVie's quarterly reports through 2027 for explicit QULIPTA sales figures or commentary on migraine franchise trends.
